Controlled release nanoparticle having bound oligonucleotide for targeted delivery
AssigneeMassachusetts Institute of Technology
InventorsOmid C. Farokhzad, Sang Yong Jon, Robert S. Langer
Life of this patent
Estimating the term…
Abstract
The present invention relates to a conjugate that includes a nucleic acid ligand bound to a controlled release polymer system, a pharmaceutical composition that contains the conjugate, and methods of treatment using the conjugate. The controlled release polymer system includes an agent such as a therapeutic, diagnostic, prognostic, or prophylactic agent. The nucleic acid ligand that is bound to the controlled release polymer system, binds selectively to a target, such as a cell surface antigen, and thereby delivers the controlled release polymer system to the target.
Claims23
A controlled release polymer nanoparticle, comprising:
- a therapeutic or diagnostic agent incorporated in the controlled release polymer nanoparticle;
- a nucleic acid ligand comprising an oligonucleotide bound to the surface of the controlled release polymer nanoparticle that selectively binds to a target cell or tissue, and thereby delivers the controlled release polymer nanoparticle to the target cell or tissue;
- wherein the controlled release polymer nanoparticle carries a neutral to negative charge on its surface, wherein the bound oligonucleotide has a folded three-dimensional conformation resulting from intramolecular interactions;
- and
- wherein the nucleic acid ligand is an aptamer.
A controlled release polymer nanoparticle, comprising;
- a therapeutic or diagnostic agent incorporated in the controlled release polymer nanoparticle;
- and a nucleic acid ligand comprising an oligonucleotide bound to the surface of the controlled release polymer nanoparticle that selectively binds to a target cell or tissue, and thereby delivers the controlled release polymer nanoparticle to the target cell or tissue;
- wherein the controlled release polymer nanoparticle carries a neutral to negative charge on its surface;
- and wherein the bound oligonucleotide has a folded three-dimensional conformation resulting from intramolecular interactions;
- wherein the nucleic acid ligand binds to an antigen.
A controlled release polymer nanoparticle, comprising;
- a therapeutic or diagnostic agent incorporated in the controlled release polymer nanoparticle;
- and a nucleic acid ligand comprising an oligonucleotide bound to the surface of the controlled release polymer nanoparticle that selectively binds to a target cell or tissue, and thereby delivers the controlled release polymer nanoparticle to the target cell or tissue;
- wherein the controlled release polymer nanoparticle carries a neutral to negative charge on its surface;
- and wherein the bound oligonucleotide has a folded three-dimensional conformation resulting from intramolecular interactions;
- wherein the therapeutic agent is a protein drug selected from the group consisting of an antibody, an antibody fragment, a recombinant antibody, a recombinant protein, a purified protein, a peptide, an amino acid and combinations thereof.
Dependencies are inferred from the claim text.